Login / Signup

Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.

Luigi PontieriMorten BlinkenbergStephan BramowViktoria PappPeter V RasmussenMatthias KantJakob SchäferHenrik K MathiesenMichael B JensenGeorgi SirakovJonas M BergTine Iskov KoppHanna JoensenFinn SellebjergMelinda Magyari
Published in: European journal of neurology (2021)
It is shown that most MS patients treated with ocrelizumab are clinically stabilized and with an adverse event profile consistent with the experience from the pivotal clinical trials.
Keyphrases
  • multiple sclerosis
  • clinical trial
  • ms ms
  • white matter
  • emergency department
  • combination therapy
  • phase ii
  • randomized controlled trial
  • study protocol
  • adverse drug